open access

Vol 13, No 6 (2018)
Original Papers
Published online: 2018-09-17
Get Citation

Contemporary use of ticagrelor in Polish medical centres as a reflection of antiplatelet treatment guidelines adherence

Przemysław Paciorek, Jakub Ratajczak
DOI: 10.5603/FC.a2018.0098
·
Folia Cardiologica 2018;13(6):503-509.

open access

Vol 13, No 6 (2018)
Original Papers
Published online: 2018-09-17

Abstract

Introduction. Ticagrelor is the newest P2Y12 inhibitor recommended as the first treatment option for acute myocardial infarction both with and without ST-segment elevation. Recent studies have revealed unsatisfactory use of novel P2Y12 inhibitors. The aim of our study was to assess the contemporary use of ticagrelor in major medical centres located in Kuyavian-Pomeranian, Pomeranian, and Warmian-Masurian voivodships. Materials and methods. Retrospective analysis of hospital records regarding the number of ticagrelor tablets purchased monthly was performed covering a three-year period from January 2015 to December 2017. Data from 15 major medical centres was analysed. Results. A total of 78,871 tablets of ticagrelor were purchased over the study period, with a monthly median of 2,013.5 and an interquartile range (IQR) of 1,255–2,996. The amount of ticagrelor increased monthly by 7.9%. The lowest monthly value (294, 0.37%) was recorded in the first month, while the highest (4,550, 5.77%) was in October 2017. The median of tablets purchased in 2017 (3,934, IQR 3,010–4,270) was over four times greater than in 2015 (980, IQR 728–1,288, p < 0.001) and more than double that in 2016 (1,689, IQR 1,353–2,479, p = 0.012). The highest reported amount of the drug in one centre (16,296, 20.6%) was 291 times greater than the amount in the centre with the lowest ticagrelor use (56, 0.07%, p = 0.27). Conclusions. The use of ticagrelor has been significantly increasing in recent years, which reflects the implementation of current guidelines by medical centres. Substantial heterogeneity regarding the use of ticagrelor is observed within particular centres.

Abstract

Introduction. Ticagrelor is the newest P2Y12 inhibitor recommended as the first treatment option for acute myocardial infarction both with and without ST-segment elevation. Recent studies have revealed unsatisfactory use of novel P2Y12 inhibitors. The aim of our study was to assess the contemporary use of ticagrelor in major medical centres located in Kuyavian-Pomeranian, Pomeranian, and Warmian-Masurian voivodships. Materials and methods. Retrospective analysis of hospital records regarding the number of ticagrelor tablets purchased monthly was performed covering a three-year period from January 2015 to December 2017. Data from 15 major medical centres was analysed. Results. A total of 78,871 tablets of ticagrelor were purchased over the study period, with a monthly median of 2,013.5 and an interquartile range (IQR) of 1,255–2,996. The amount of ticagrelor increased monthly by 7.9%. The lowest monthly value (294, 0.37%) was recorded in the first month, while the highest (4,550, 5.77%) was in October 2017. The median of tablets purchased in 2017 (3,934, IQR 3,010–4,270) was over four times greater than in 2015 (980, IQR 728–1,288, p < 0.001) and more than double that in 2016 (1,689, IQR 1,353–2,479, p = 0.012). The highest reported amount of the drug in one centre (16,296, 20.6%) was 291 times greater than the amount in the centre with the lowest ticagrelor use (56, 0.07%, p = 0.27). Conclusions. The use of ticagrelor has been significantly increasing in recent years, which reflects the implementation of current guidelines by medical centres. Substantial heterogeneity regarding the use of ticagrelor is observed within particular centres.
Get Citation

Keywords

ticagrelor, P2Y12 inhibitor, guidelines adherence

About this article
Title

Contemporary use of ticagrelor in Polish medical centres as a reflection of antiplatelet treatment guidelines adherence

Journal

Folia Cardiologica

Issue

Vol 13, No 6 (2018)

Pages

503-509

Published online

2018-09-17

DOI

10.5603/FC.a2018.0098

Bibliographic record

Folia Cardiologica 2018;13(6):503-509.

Keywords

ticagrelor
P2Y12 inhibitor
guidelines adherence

Authors

Przemysław Paciorek
Jakub Ratajczak

References (22)
  1. Nawarskas JJ, Clark SM. Ticagrelor: a novel reversible oral antiplatelet agent. Cardiol Rev. 2011; 19(2): 95–100.
  2. Navarese EP, Buffon A, Kozinski M, et al. A critical overview on ticagrelor in acute coronary syndromes. QJM. 2013; 106(2): 105–115.
  3. Roffi M, Patrono C, Collet JP, et al. ESC Scientific Document Group . 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(3): 267–315.
  4. Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol. 2016; 215: 201–208.
  5. Adamski P, Sikora J, Laskowska E, et al. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. PLoS One. 2017; 12(10): e0186013.
  6. Adamski P, Ostrowska M, Sikora J, et al. Comparison of ticagrelor pharmacokinetics and pharmacodynamics in STEMI and NSTEMI patients (PINPOINT): protocol for a prospective, observational, single-centre study. BMJ Open. 2017; 7(4): e013218.
  7. Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
  8. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016; 37(3): 245–252.
  9. Siller-Matula JM, Trenk D, Schrör K, et al. EPA (European Platelet Academy). Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv. 2013; 6(11): 1111–1128.
  10. Steg PhG, James SK, Atar D, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20): 2569–2619.
  11. Erlikh A, Gratsiansky NA. Adherence to guidelines on management of acute coronary syndrome in Russian hospitals is better in lower risk patients and this is associated with better outcomes of hospitalization. Eur Heart J. 2013; 34(Suppl 1): P485–P485.
  12. Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Curr Med Res Opin. 2016; 32(8): 1441–1451.
  13. Rakowski T, Siudak Z, Dziewierz A, et al. Contemporary use of P2Y inhibitors in patients with ST-segment elevation myocardial infarction referred to primary percutaneous coronary interventions in Poland: Data from ORPKI national registry. J Thromb Thrombolysis. 2018; 45(1): 151–157.
  14. Carrabba N, Bellandi B, Parodi G, et al. APpropriateness Assessment in Antiplatelet THerapY (APATHY) registry: Insight from current clinical practice. Int J Cardiol. 2017; 244: 13–16.
  15. De Luca L, Leonardi S, Cavallini C, et al. EYESHOT Investigators. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. Eur Heart J Acute Cardiovasc Care. 2015; 4(5): 441–452.
  16. Tscharre M, Egger F, Machata M, et al. Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. PLoS One. 2017; 12(6): e0179349.
  17. Alexopoulos D, Goudevenos JA, Xanthopoulou I, et al. GRAPE Investigators. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). Int J Cardiol. 2013; 168(6): 5329–5335.
  18. Kubica J, Adamski P, Paciorek P, et al. Anti-aggregation therapy in patients with acute coronary syndrome - recommendations for medical emergency teams. Experts' standpoint. Kardiol Pol. 2017; 75(4): 399–408.
  19. Sahlén A, Varenhorst C, Lagerqvist Bo, et al. Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Eur Heart J Cardiovasc Pharmacother. 2016; 2(1): 5–12.
  20. Niezgoda P, Sikora J, Barańska M, et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. Thromb Haemost. 2017; 117(4): 718–726.
  21. Kubica J, Adamski P, Buszko K, et al. Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. Eur Heart J Cardiovasc Pharmacother. 2018; 4(3): 152–157.
  22. Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opin Pharmacother. 2016; 17(17): 2291–2306.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl